Acta Scientific Paediatrics (ISSN: 2581-883X)

Review ArticleVolume 4 Issue 5

Recent Approaches in the Management of Difficult to Treat Asthma in Pediatric Population - A Brief Review

Edwin Dias1,2* and Shwetha N3

1Professor and Head, Department of Pediatrics, Srinivas Institute of Medical Sciences and Research Centre, Mangalore, Karnataka State, India
2Adjunct Research Professor, College of Allied Health Sciences, Srinivas University, Mangalore, India
3Final Year Pharm D., Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka State, India

*Corresponding Author: Edwin Dias, Professor and Head, Department of Pediatrics, Srinivas Institute of Medical Sciences and Research Centre, Mangalore, Karnataka State, India.

Received: April 26, 2021; Published: May 16, 2021

Citation: Edwin Dias and Shwetha N. “Recent Approaches in the Management of Difficult to Treat Asthma in Pediatric Population - A Brief Review”. Acta Scientific Paediatrics 4.6 (2021): 24-35.

Abstract

Introduction: Pediatric patients with difficult-to-treat asthma experience a heavy burden of exacerbations, symptoms, therapeutic failure, adverse drug reactions, and increased health care costs. Frequent cough, dyspnoea, chest tightness, and wheeze interfere with normal daily activities, sleeping, overall quality of life, and education of children. Difficult-to-treat asthma affects a small group of children with asthma but represents a challenging mix of misdiagnosis or incorrect diagnosis, multiple co-morbidities, severe airway pathophysiology, inadequate self-management, and treatment complications. Thus management of such cases requires beyond pharmacotherapy of asthma because patient-related and disease-related domains need to be considered first. Therefore, prevention of asthma exacerbations is an essential goal in difficult-to-treat asthma therapy and requires more focused individualized treatment that involves the elimination of risk factors, treatment of co-morbidities, treatment with anti-asthmatics, and improving medication adherence.

Methodology: A brief review of all the relevant standard articles was conducted.

Results: The study involved a brief review on assessment of risk factors in the pediatric population with difficult-to-treat asthma and pharmacological management i.e. optimal use of long-acting muscarinic antagonist (tiotropium), and biological monoclonal antibody treatment (Omalizumab, Mepolizumab, Dupilumab, and Benralizumab) which were found to be safe and effective in the pediatric population.

Conclusion: Management of difficult-to-treat asthma in the pediatric population requires the elimination of modifiable risk factors, treatment of co-morbidities, and treatment of exacerbations with newer agents which were found to be effective in reducing hospitalizations and frequent Emergency Department visits. Thus individualized treatment must be preferred in these patients.

Keywords: Difficult-to-Treat Asthma; Pediatrics; Risk Factors; Recent Approaches; Management

Bibliography

  1. Cloutier Michelle M., et al. "Use of asthma guidelines by primary care providers to reduce hospitalizations and emergency department visits in poor, minority, urban children”. The Journal of Pediatrics5 (2005): 591-597.
  2. Williams Seymour G., et al. "Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program”. MMWR Recommendations and reports: Morbidity and Mortality Weekly Report RR-6 (2003): 1-8.
  3. Vos Theo., et al. "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016”. The Lancet10100 (2017): 1211-1259.
  4. World Health Organization. “Disease burden and mortality estimates” (2018).
  5. Guilbert Theresa W., et al. "Severe asthma in children”. The Journal of Allergy and Clinical Immunology: In Practice5 (2014): 489-500.
  6. Bousquet J., et al. "GINA guidelines on asthma and beyond”. Allergy2 (2007): 102-112.
  7. Boulet Louis-Philippe., et al. "The revised 2014 GINA strategy report: opportunities for change”. Current Opinion in Pulmonary Medicine1 (2015): 1-7.
  8. Sennhauser Felix H., et al. "The burden of asthma in children: a European perspective”. Paediatric Respiratory Reviews1 (2005): 2-7.
  9. Zahran Hatice S., et al. "Vital signs: asthma in children—United States, 2001-2016”. Morbidity and Mortality Weekly Report5 (2018): 149.
  10. Plaza-Martín A M., et al. "Prevalence and clinical profile of difficult-to-control severe asthma in children: Results from pneumology and allergy hospital units in Spain”. Allergologia et Immunopathologia6 (2014): 510-517.
  11. Ten Brinke A., et al. "Risk factors of frequent exacerbations in difficult-to-treat asthma”. European Respiratory Journal5 (2005): 812-818.
  12. Gendo Karna and Matthew J Lodewick. "Asthma economics: focusing on therapies that improve costly outcomes”. Current Opinion in Pulmonary Medicine1 (2005): 43-50.
  13. Trivedi Michelle and Eve Denton. "Asthma in children and adults—what are the differences and what can they tell us about asthma?”. Frontiers in Pediatrics7 (2019): 256.
  14. Bodzenta-Łukaszyk Anna., et al. "The statement of the Polish Society of Allergology experts on the treatment of difficult-to-treat asthma”. Advances in Respiratory Medicine4 (2015): 324-334.
  15. Robinson DS., et al. "Systematic assessment of difficult-to-treat asthma”. European Respiratory Journal3 (2003): 478-483.
  16. Le Annie V and Ronald A Simon. "The difficult-to-control asthmatic: a systematic approach”. Allergy, Asthma and Clinical Immunology3 (2006): 1-8.
  17. Ullmann Nicola., et al. "Asthma: differential diagnosis and comorbidities”. Frontiers in Pediatrics6 (2018): 276.
  18. Spector Sheldon. "Noncompliance with asthma therapy—are there solutions?”. Journal of asthma5 (2000): 381-388.
  19. Celano Marianne, et al. "Treatment adherence among low-income children with asthma”. Journal of Pediatric Psychology6 (1998): 345-349.
  20. Murphy A C., et al. "P174 Identifying non-adherence with asthma medication and the relationship to clinical outcomes amongst adults with difficult-to-control asthma”. Thorax4 (2010): A151-A151.
  21. Buston Katie M and Stuart F Wood. "Non-compliance amongst adolescents with asthma: listening to what they tell us about self-management”. Family Practice2 (2000): 134-138.
  22. Giraud V and N Roche. "Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability”. European Respiratory Journal2 (2002): 246-251.
  23. Katon Wayne., et al. "The prevalence of DSM-IV anxiety and depressive disorders in youth with asthma compared with controls”. Journal of Adolescent Health5 (2007): 455-463.
  24. McQuaid Elizabeth L., et al. "Behavioral adjustment in children with asthma: a meta-analysis”. Journal of Developmental and Behavioral Pediatrics6 (2001): 430-439.
  25. Marin Teresa J., et al. "Double-exposure to acute stress and chronic family stress is associated with immune changes in children with asthma”. Psychosomatic Medicine4 (2009): 378.
  26. Rhee Hyekyun., et al. "Barriers to asthma self‐management in adolescents: Relationships to psychosocial factors”. Pediatric Pulmonology2 (2009): 183-191.
  27. McCorkle Laura Steed. “A study of the relationships of self-efficacy of self-management of asthma and asthma self-management knowledge”. Diss. Texas A&M University (2005).
  28. Hauser‐Cram Penny., et al. "I. Introduction”. Monographs of the Society for Research in Child Development3 (2001): 1-5.
  29. Bauman Laurie J., et al. "Cumulative social disadvantage and child health”. Pediatrics4 (2006): 1321-1328.
  30. Brkic Fuad., et al. "Cochlear implantation in children: socioeconomic family characteristics”. Medical Archives1 (2010): 25.
  31. Majnemer Annette., et al. "Determinants of life quality in school-age children with cerebral palsy”. The Journal of Pediatrics5 (2007): 470-475.
  32. Klok Ted., et al. "Every parent tells a story: why non-adherence may persist in children receiving guideline-based comprehensive asthma care”. Journal of Asthma1 (2014): 106-112.
  33. Miller Bruce D., et al. "Depressed children with asthma evidence increased airway resistance:“vagal bias” as a mechanism?”. Journal of Allergy and Clinical Immunology1 (2009): 66-73.
  34. Daisey Joan M., et al. "Indoor air quality, ventilation and health symptoms in schools: an analysis of existing information”. Indoor AirLBNL-48287 (2003).
  35. Hancox R J., et al. "Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled β-agonist treatment”. Respiratory Medicine8 (2000): 767-771.
  36. Stanford Richard H., et al. "Short-acting β-agonist use and its ability to predict future asthma-related outcomes”. Annals of Allergy, Asthma and Immunology6 (2012): 403-407.
  37. Suissa Samy., et al. "Low-dose inhaled corticosteroids and the prevention of death from asthma”. New England Journal of Medicine5 (2000): 332-336.
  38. Ind P W., et al. "Anticholinergic blockade of beta-blocker-induced bronchoconstriction”. American Review of Respiratory Disease (2012).
  39. Denson-Lino J M., et al. "Effect of economic status on the use of house dust mite avoidance measures in asthmatic children”. Annals of Allergy2 (1993): 130-132.
  40. Kim Byung-Keun., et al. "Evaluation and management of difficult-to-treat and severe asthma: an expert opinion from the Korean academy of asthma, allergy and clinical immunology, the working group on severe asthma”. Allergy, Asthma and Immunology Research6 (2020): 910.
  41. Hew Mark., et al. "Systematic assessment of difficult-to-treat asthma: principles and perspectives”. The Journal of Allergy and Clinical Immunology: In Practice7 (2020): 2222-2233.
  42. Giraud V and N Roche. "Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability”. European Respiratory Journal2 (2002): 246-251.
  43. Fink James B and Bruce K Rubin. "Problems with inhaler use: a call for improved clinician and patient education”. Respiratory Care10 (2005): 1360-1375.
  44. Dolovich M A., et al. "Consensus statement: aerosols and delivery devices. American Association for Respiratory Care”. Respiratory Care6 (2000): 589-596.
  45. Global Initiative for Asthma - GINA. Diagnosis and Management of Difficult-to-treat and Severe Asthma - Global Initiative for Asthma – GINA (2019).
  46. Narasimhan Krishnan. "Difficult-to-Treat and Severe Asthma: Management Strategies”. American Family Physician5 (2021): 286-290.
  47. Busse William W., et al. "Combined analysis of asthma safety trials of long-acting β2-agonists”. New England Journal of Medicine26 (2018): 2497-2505.
  48. Sobieraj Diana M., et al. "Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis”. JAMA14 (2018): 1473-1484.
  49. Reiter J., et al. "Macrolides for the long‐term management of asthma-a meta‐analysis of randomized clinical trials”. Allergy8 (2013): 1040-1049.
  50. Normansell Rebecca., et al. "Omalizumab for asthma in adults and children”. Cochrane Database of Systematic Reviews1 (2014).
  51. Ortega Hector G., et al. "Mepolizumab treatment in patients with severe eosinophilic asthma”. New England Journal of Medicine13 (2014): 1198-1207.
  52. Nair Parameswaran., et al. "Oral glucocorticoid-sparing effect of benralizumab in severe asthma”. New England Journal of Medicine25 (2017): 2448-2458.
  53. Castro Mario., et al. "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma”. New England Journal of Medicine26 (2018): 2486-2496.
  54. Wang, Kathleen Y., et al. "Efficacy and safety of omalizumab in pediatric patients with high immunoglobulin E levels: A case series”. Allergy and Asthma Proceedings 39.4 (2018).
  55. Licari Amelia, et al. "Immunomodulation in pediatric asthma”. Frontiers in Pediatrics7 (2019): 289.
  56. Agache Ioana., et al. "Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma”. Allergy5 (2020): 1058-1068.
  57. Agache Ioana., et al. "Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines‐recommendations on the use of biologicals in severe asthma”. Allergy5 (2020): 1043-1057.
  58. Gupta Atul., et al. "What is new in the management of childhood asthma?”. The Indian Journal of Pediatrics9 (2018): 773-781.
  59. Vogelberg Christian. "Emerging role of long-acting anticholinergics in children with asthma”. Current Opinion in Pulmonary Medicine1 (2016): 74-79.
  60. Hamelmann Eckard and Stanley J Szefler. "Efficacy and safety of tiotropium in children and adolescents”. Drugs3 (2018): 327-338.
  61. Rodrigo Gustavo J and Hugo Neffen. "Efficacy and safety of tiotropium in school‐age children with moderate‐to‐severe symptomatic asthma: A systematic review”. Pediatric Allergy and Immunology6 (2017): 573-578.
  62. Hamelmann Eckard., et al. "Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial”. Journal of Allergy and Clinical Immunology2 (2016): 441-450.
  63. Hamelmann Eckard., et al. "A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma”. European Respiratory Journal1 (2017).
  64. Vogelberg Christian, et al. "Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma”. The Journal of Allergy and Clinical Immunology: In Practice6 (2018): 2160-2162.
  65. Szefler Stanley J., et al. "A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma”. Journal of Allergy and Clinical Immunology5 (2017): 1277-1287.
  66. Bisgaard Hans., et al. "P154 Safety of tiotropium in pre-school children with symptomatic persistent asthma”. (2016): A166-A167.
  67. Vrijlandt Elianne JLE., et al. "Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial”. The Lancet Respiratory Medicine2 (2018): 127-137.
  68. Panickar Jayachandran R., et al. "Intramuscular triamcinolone for difficult asthma”. Pediatric pulmonology5 (2005): 421-425.
  69. Varga Eva-Maria., et al. "Immunomodulatory treatment strategies for allergic diseases”. Current Drug Targets-Inflammation and Allergy1 (2003): 31-46.
  70. Velastegui Claudia, et al. "Impact of asthma among primary attention children”. Revista medica de Chile2 (2010): 205-212.

Copyright: © 2021 Edwin Dias and Shwetha N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US